These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28347776)

  • 1. Identification of new SNPs associated with severe toxicity to capecitabine.
    Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
    Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
    Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity.
    Pellicer M; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Rueda D; Martínez J; Pachón V; Longo F; Martínez V; Iglesias I; Salvador S; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2017 Aug; 18(13):1215-1223. PubMed ID: 28745575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
    García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
    Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
    Saif MW
    Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
    Gonzalez-Haba E; García MI; Cortejoso L; López-Lillo C; Barrueco N; García-Alfonso P; Alvarez S; Jiménez JL; Martín ML; Muñóz-Fernández MA; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2010 Dec; 11(12):1715-23. PubMed ID: 21142915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
    Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
    Milano G
    Scand J Clin Lab Invest Suppl; 2016; 245():S30-3. PubMed ID: 27454530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
    Rumiato E; Boldrin E; Amadori A; Saggioro D
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
    Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
    Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
    Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
    Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
    Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.